FDLI remains committed to providing high-quality educational programs while keeping our members and event attendees safe during the current pandemic. Currently, we plan on moving forward with the Tobacco and Nicotine Products Regulation and Policy Conference as an in-person conference. However, we also recognize that we do not know how long the current situation will persist. We will convert this event into a virtual conference on the same dates should we decide this is needed to ensure the safety of all participants.

Why Attend?

Last Year’s Agenda
Location & CLE

Join a diverse group of stakeholders – public health advocates, researchers, manufacturers, lawyers, consumer interest groups, entrepreneurs, governmental agencies, and others – for this two-day conference on effectively regulating the broad spectrum of tobacco and nicotine products in the US. Attendees will hear directly from FDA about the latest updates on regulations, guidance documents, and other initiatives. The conference will also include numerous discussions of timely tobacco and nicotine product issues and feature interactive dialogues between the panelists and audience.


Industry & Firms

  • +$500 for non-members


  • +$100 for non-members


  • +$100 for non-members


  • +$100 for non-members


  • full-time students only

Full time employees of 501(c)(3) charitable organizations are eligible to apply for a registration waiver.  Please email [email protected] for more information.


Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


Sponsorship opportunities are available. Please let us know if you would like more information.

Gold Sponsor

Call For Proposals

FDLI and the Conference Planning Committee thanks those who participated in the Call for Proposals this spring. The input received from industry stakeholders helps us plan a timely and relevant program. If you submitted a proposal, you will be notified of the status of your proposal in July.

Planning Committee

Issa Abuaita, Al Fakher USA
Scott D. Ballin, Public Health Consultant
James Baumberger, American Academy of Pediatrics
Aruni Bhatnagar, American Heart Association
Tara Lin Couch, EAS Consulting Group, LLC
Michael Cummings, Medical University of South Carolina
Brittani Cushman, Turning Point Brands, Inc.
Stacey Younger Gagosian*, Truth Iniative
Thomas Glynn, Stanford University School of Medicine
Robyn Gougelet, Pinney Associates, Inc.
Ben Haas, Latham & Watkins LLP
Bryan M. Haynes, Troutman Sanders LLP
Dennis Henigan, Campaign for Tobacco-Free Kids
Desmond Jenson, Public Health Law Center – Tobacco Control Legal Consortium
Eshael Johnson, CTP, FDA
Ondrej Koumal, Philip Morris International
Eric N. Lindblom, O’Neill Institute for National and Global Health Law, Georgetown Law
Joe Murillo, JUUL Labs
John Marshall, Altria Client Services LLC
Kelley Coleman Nduom, CDER, FDA
Henry Roemer, Specialty Tobacco Council, Inc.
Barry Schaevitz, Fox Rothschild LLP
Jim M. Solyst, Swedish Match North America
Mark J. Vaders, Womble Bond Dickinson (US) LLP